

06 Mar 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; Janssen/Legend's US pricing and launch plans for Carvykti; Ipsen seeks multiple licensing deals; and the fourth in the *Scrip Asks* series looks at prospects for therapeutic advances.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 4 March 2022, including: the pharma industry reacts to the Ukraine situation; a guide to targeted protein degradation; [\*Janssen Pharmaceutical Cos./Legend Biotech Corp.\*](#)'s US pricing and launch plans for Carvykti; [\*Ipsen SA\*](#) seeks multiple licensing deals; and the fourth in the *Scrip Asks* series looks at prospects for therapeutic advances.

This and all our other podcasts are available on the Informa Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Biotech CEOs Take Assertive Stance On Ukraine War, While PhRMA Remains More Neutral\*](#)" - Scrip, 1 Mar, 2022.)

(Also see "[\*Scrip's Rough Guide To Targeted Protein Degradation\*](#)" - Scrip, 28 Feb, 2022.)

(Also see "[\*Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti\*](#)" - Scrip, 28 Feb, 2022.)

# SCRIP

CITELINE COMMERCIAL

(Also see "[Ipsen Seeks Success Outside Big Pharma's Hunting Grounds](#)" - Scrip, 2 Mar, 2022.)

(Also see "[Scrip Asks...What Does 2022 Hold For Biopharma? Part 4: Therapeutic Area Advances](#)" - Scrip, 1 Mar, 2022.)

[Click here to explore this interactive content online](#) 